Respiratory Syncytial Virus (RSV)
Conditions
Keywords
Antibodies, Respiratory syncytial virus, Safety, Healthy adults, Immunogenicity
Brief summary
The purpose of this study is to evaluate the safety and immunogenicity of two doses of the investigational RSV F subunit vaccine administered intramuscularly (IM). In this current Phase 1, first-in-human study, the three different antigen amounts that have been selected will be evaluated in a stepwise manner in three different cohorts (Cohort 1: low dosage of RSV F subunit vaccine, Cohort 2: middle dosage of RSV F subunit vaccine, and Cohort 3: high dosage of RSV F subunit vaccine). In addition, the effect of an adjuvant, either aluminum hydroxide or MF59, and antibody kinetics post-vaccination at different time points will be evaluated as compared to unadjuvanted RSV F subunit vaccine at the same dosage levels.
Interventions
BIOLOGICALRSV F subunit 45 μg No adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 45 μg Aluminum hydroxide adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 45 μg MF59 adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 90 μg No adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 90 μg Aluminum hydroxide adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 90 μg MF59 adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 135 μg No adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 135 μg Aluminum hydroxide adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
BIOLOGICALRSV F subunit 135 μg MF59 adjuvant
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
DRUGPlacebo
2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy males and non-pregnant females 18 to 45 years of age at time of enrollment. 2. Individuals who have given written consent after the nature of the study has been explained according to local regulatory requirements. 3. Individuals in good health as determined by the outcome of the medical history, physical examination and clinical judgment of the investigator. 4. Individuals who can comply with the study procedures and are available for follow up.
Exclusion criteria
1. Individuals with any severe chronic or acute disease. 2. Individuals with a history of illness or with an ongoing illness that may pose additional risk to the subject if he/she participates in the study, including the following: * History of any chronic respiratory illness, including current diagnosis of asthma within 2 years, exercise induced wheezing, reactive airway disease, emphysema, chronic bronchitis, cystic fibrosis or chronic obstructive pulmonary disease (COPD). * Any respiratory illness within 7 days prior to receiving the first study injection. * Any active pulmonary infection or other inflammatory conditions, even in the absence of febrile episodes, within 14 days prior to the first study injection. * Hepatitis B or hepatitis C infection. 3. Individuals who have had a malignancy or lymphoproliferative disorder within the past 5 years. 4. Individuals with known or suspected impairment of the immune system including but not limited to HIV, autoimmune disorders, immunosuppressive therapy, and diabetes mellitus. 5. Individuals with any history of progressive or severe neurologic disorder, seizure disorder or Guillian-Barré syndrome. 6. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time. 7. Individuals with a BMI \> 35 kg/m2. BMI is to be calculated by the following formula: subject weight at baseline divided by subject height in meters multiplied by the subject height in meters. The numerical result will be rounded to the nearest 0.1. 8. Individuals who are allergic to any of the vaccine components, or with a history of anaphylaxis after vaccination. 9. Individuals who during the 90 days prior to enrollment receive any medications or other treatments that may adversely affect the immune system such as allergy injections, immune globulin, interferon, immunomodulators, cytotoxic drugs or other drugs known to be frequently associated with significant major organ toxicity. 10. Individuals who receive systemic immunosuppressive agents including steroids. Prior corticosteroid therapy should be discontinued 28 days prior to enrollment. Individuals using inhaled or topical corticosteroids will be permitted. 11. Receipt or donation of blood or blood products 8 weeks prior to vaccination or planned receipt or donation during the study period. 12. Individuals participating in any clinical trial with another investigational product 28 days prior to receiving the first study vaccination or intent to participate in another clinical study at any time during the conduct of this study. 13. Individuals who have received any vaccine 28 days prior to enrollment in this study, or who plan to receive any non-study vaccines within 28 days of the second dose of study vaccine. 14. Individuals with any clinically significant abnormal safety laboratory result, as judged by the investigator. 15. If female, 'of childbearing potential', sexually active and has not used any of the 'acceptable contraceptive methods' for at least two months prior to study entry. Childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least two years; sterile status after bilateral tubal ligation for at least one year, immediately after bilateral oophorectomy or after hysterectomy. Acceptable methods of birth control are defined as one or more of the following: * Hormonal contraceptives. * Barrier each and every time during intercourse. * Intrauterine device (IUD). * Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least six months prior to subject's study entry. 16. If female subject of childbearing potential and have a positive urine pregnancy test prior to study vaccinations, or are currently lactating. 17. If female of childbearing potential and sexually active, refusal to use an 'acceptable contraceptive method' through to three weeks after last study vaccination. 18. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study. 19. Individuals with a history of drug or alcohol abuse within the past 2 years. 20. Individuals who are acting as study personnel or immediate family members or the spouse of study personnel. 21. Individuals with a body temperature ≥38 °C (≥100.4◦F) within 3 days of intended study vaccination. 22. Individuals with any condition that, in the opinion of the investigator, would interfere with the primary study objectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | At Day 57 | Immunogenicity was measured in terms of the Geometric mean titers (GMTs) of the serum anti-RSV neutralizing antibody (NAb) titers at Day 57 (28 days after the second dose). |
| Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | At Day 57 | Immunogenicity was measured in terms of percentage of subjects with a ≥ 4-fold increase in serum anti-RSV NAb titers, from Day 1 (baseline) to Day 57 (28 days after the second dose). |
| Number of Subjects With Any Solicited Local Symptoms | Within 30 minutes after each vaccination | Assessed solicited local symptoms were: induration, swelling, erythema and pain. Any induration/swelling/erythema = induration/swelling/erythema spreading beyond 25 millimeters (mm) of injection site. Any pain = occurrence of the symptom regardless of intensity grade. |
| Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Within 30 minutes after each vaccination | Assessed solicited systemic symptoms were: nausea, fatigue, myalgia, arthralgia, headache, fever (body temperature ≥ 38.0°C), chills, coughing, diarrhea, rhinorrhea and wheezing. Other solicited data included: prevention of pain and/or fever and treatment of pain and/or fever. Any = occurrence of the symptom regardless of intensity grade. |
| Number of Subjects With Unsolicited Adverse Events (AEs) | From Day 1 to Day 28 after each vaccination | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | From study start (Day 1) until study completion (Day 394) | SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity, congenital anomaly or birth defect. Any SAE = occurrence of the SAE regardless of intensity grade. Possibly or probably related SAE = SAE assessed by the investigator as possibly or probably related to the study vaccination. Other significant AE(s) assessed include unsolicited medically attended AEs, unsolicited AEs leading to study withdrawal, new onset of chronic diseases (NOCDs) and adverse events of special interest (AESIs). Medically attended AE = an adverse event that leads to an unscheduled visit to a healthcare practitioner. NOCD = an adverse event that represents a new diagnosis of a chronic medical condition that was not present or suspected in a subject prior to study enrollment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | At Day 1, Day 29 and Day 181 | Immunogenicity was measured in terms of GMTs of the serum anti-RSV neutralizing antibody (NAb) titers at Day 1, Day 29 (28 days after the first dose) and Day 181 (six months after the first dose). |
| Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | At Day 1, Day 29, Day 57 and Day 181 | Immunogenicity was measured in terms of the ratio of RSV F serum Nab titers to each of the RSV F serum total binding antibody titers to RSV proteins F, G and N at Days 1, 29, 57 and 181. |
| Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | At Day 29 and at Day 181 | Immunogenicity was measured in terms of percentage of subjects with a ≥ 4-fold increase in serum anti-RSV NAb titers from Day 1 to Day 29 (28 days after the first dose) and from Day 1 to Day 181 (six months after the first dose). |
| Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | At Day 29, Day 57 and Day 181 | Immunogenicity was measured in terms of the percentage of subjects at Day 29 (28 days after the first dose), Day 57 (28 days after the second dose) and Day 181 (six months after the first dose) with serum anti-RSV NAb titers greater than the 3rd quartile of serum anti-RSV NAb titers at Day 1 (baseline). |
| Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | At Day 1, Day 29, Day 57 and Day 181 | Immunogenicity was measured in terms of the geometric mean titers (GMTs) of the serum total binding antibody to each of the RSV proteins F, G and N at Day 1 (baseline), Day 29 (28 days after the first dose), Day 57 (28 days after the second dose) and Day 181 (six months after the first dose). |
| Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | At Day 29, Day 57 and Day 181 | Immunogenicity was measured in terms of the percentage of subjects with a ≥ 4-fold increase in serum total binding antibody to each of the RSV Proteins F, G and N from Day 1 (baseline) to all time points (Day 29 \[28 days after the first dose\], Day 57 \[28 days after the second dose\], and Day 181 \[six months after the first dose\]). |
| Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | At Day 29, Day 57 and Day 181 | Immunogenicity was measured in terms of the percentage of subjects at Day 29 (28 days after the first dose), Day 57 (28 days after the second dose) and Day 181 (six months after the first dose), with serum total binding antibody titers to each of the RSV proteins F, G, and N greater than the 3rd quartile of serum total binding antibody titers to RSV protein F at Day 1 (baseline). |
Countries
Belgium
Participant flow
Recruitment details
Subjects were enrolled from one site in Belgium.
Pre-assignment details
All subjects enrolled were included in the trial.
Participants by arm
| Arm | Count |
|---|---|
| RSV F 45 No Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine \[45 μg\], with no adjuvant. | 24 |
| RSV F 45 Alum Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine \[45 μg\], with aluminum hydroxide adjuvant. | 24 |
| RSV F 45 MF59 Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine \[45 μg\], with MF59 adjuvant. | 24 |
| Placebo 1 Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine \[45 μg\], Cohort 2: middle dosage of RSV F subunit vaccine \[90 μg\], and Cohort 3: high dosage of RSV F subunit vaccine \[135 μg\]). This placebo group belongs to Cohort 1. | 24 |
| RSV F 90 No Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine \[90 μg\], with no adjuvant. | 24 |
| RSV F 90 Alum Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine \[90 μg\], with aluminum hydroxide adjuvant. | 24 |
| RSV F 90 MF59 Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine \[90 μg\], with MF59 adjuvant. | 24 |
| Placebo 2 Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine \[45 μg\], Cohort 2: middle dosage of RSV F subunit vaccine \[90 μg\], and Cohort 3: high dosage of RSV F subunit vaccine \[135 μg\]). This placebo group belongs to Cohort 2. | 24 |
| RSV F 135 No Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine \[135 μg\], with no adjuvant. | 24 |
| RSV F 135 Alum Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine \[135 μg\], with aluminum hydroxide adjuvant. | 24 |
| RSV F 135 MF59 Adj Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine \[135 μg\], with MF59 adjuvant. | 24 |
| Placebo 3 Group Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine \[45 μg\], Cohort 2: middle dosage of RSV F subunit vaccine \[90 μg\], and Cohort 3: high dosage of RSV F subunit vaccine \[135 μg\]). This placebo group belongs to Cohort 3. | 24 |
| Total | 288 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | RSV F 45 No Adj Group | RSV F 45 Alum Adj Group | RSV F 45 MF59 Adj Group | Placebo 1 Group | RSV F 90 No Adj Group | RSV F 90 Alum Adj Group | RSV F 90 MF59 Adj Group | Placebo 2 Group | RSV F 135 No Adj Group | RSV F 135 Alum Adj Group | RSV F 135 MF59 Adj Group | Placebo 3 Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 28.6 Years STANDARD_DEVIATION 6.8 | 27.7 Years STANDARD_DEVIATION 6.55 | 30.2 Years STANDARD_DEVIATION 7.9 | 30.3 Years STANDARD_DEVIATION 7.62 | 30.4 Years STANDARD_DEVIATION 8.31 | 31.2 Years STANDARD_DEVIATION 7.47 | 27.6 Years STANDARD_DEVIATION 6.84 | 28 Years STANDARD_DEVIATION 7.3 | 28.3 Years STANDARD_DEVIATION 6.8 | 29.5 Years STANDARD_DEVIATION 6.98 | 32.9 Years STANDARD_DEVIATION 8.46 | 27.9 Years STANDARD_DEVIATION 5.86 | 29.13 Years STANDARD_DEVIATION 7.24 |
| Race/Ethnicity, Customized BLACK OR AFRICAN AMERICAN | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized NOT SPECIFIED | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized WHITE | 23 Participants | 22 Participants | 24 Participants | 24 Participants | 24 Participants | 24 Participants | 24 Participants | 23 Participants | 24 Participants | 24 Participants | 24 Participants | 24 Participants | 284 Participants |
| Sex: Female, Male Female | 20 Participants | 17 Participants | 18 Participants | 18 Participants | 16 Participants | 18 Participants | 15 Participants | 14 Participants | 22 Participants | 18 Participants | 20 Participants | 20 Participants | 216 Participants |
| Sex: Female, Male Male | 4 Participants | 7 Participants | 6 Participants | 6 Participants | 8 Participants | 6 Participants | 9 Participants | 10 Participants | 2 Participants | 6 Participants | 4 Participants | 4 Participants | 72 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 | 0 / 24 |
| other Total, other adverse events | 23 / 24 | 24 / 24 | 24 / 24 | 23 / 24 | 24 / 24 | 24 / 24 | 24 / 24 | 21 / 24 | 23 / 24 | 24 / 24 | 23 / 24 | 22 / 24 |
| serious Total, serious adverse events | 1 / 24 | 1 / 24 | 1 / 24 | 0 / 24 | 1 / 24 | 0 / 24 | 4 / 24 | 0 / 24 | 1 / 24 | 2 / 24 | 0 / 24 | 0 / 24 |
Outcome results
Primary
Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers
Immunogenicity was measured in terms of the Geometric mean titers (GMTs) of the serum anti-RSV neutralizing antibody (NAb) titers at Day 57 (28 days after the second dose).
Time frame: At Day 57
Population: The analysis was based on the Per-Protocol Set (PPS), which included all subjects in the Full Analysis Set (FAS) Immunogenicity population who were not excluded due to the reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 57.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 864 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 914 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 843 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 234 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 844 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 746 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 944 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 253 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 903 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 1212 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 1316 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | 254 Titers |
Primary
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were: induration, swelling, erythema and pain. Any induration/swelling/erythema = induration/swelling/erythema spreading beyond 25 millimeters (mm) of injection site. Any pain = occurrence of the symptom regardless of intensity grade.
Time frame: From Day 1 (6 hours) to Day 7 after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 13 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 14 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 4 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 11 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 21 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 13 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 19 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 16 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 11 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 18 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 12 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 13 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 20 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 13 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 15 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 11 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 22 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 18 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 14 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 5 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 5 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
Primary
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were: induration, swelling, erythema and pain. Any induration/swelling/erythema = induration/swelling/erythema spreading beyond 25 millimeters (mm) of injection site. Any pain = occurrence of the symptom regardless of intensity grade.
Time frame: Within 30 minutes after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 4 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 4 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
Primary
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were: induration, swelling, erythema and pain. Any induration/swelling/erythema = induration/swelling/erythema spreading beyond 25 millimeters (mm) of injection site. Any pain = occurrence of the symptom regardless of intensity grade.
Time frame: From Day 1 (6 hour) through Day 3 after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 12 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 13 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 11 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 21 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 19 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 13 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 4 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 10 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 16 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 12 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 18 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 20 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 13 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 12 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 15 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 22 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 11 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 14 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 18 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 5 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 5 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 1 Participants |
Primary
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were: induration, swelling, erythema and pain. Any induration/swelling/erythema = induration/swelling/erythema spreading beyond 25 millimeters (mm) of injection site. Any pain = occurrence of the symptom regardless of intensity grade.
Time frame: From Day 4 through Day 7 after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 8 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 7 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 4 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 7 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 8 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 3 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 9 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 5 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Swelling (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Pain (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Induration (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Local Symptoms | Any Erythema (1st) | 0 Participants |
Primary
Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity
Assessed solicited systemic symptoms were: nausea, fatigue, myalgia, arthralgia, headache, fever (body temperature ≥ 38.0°C), chills, coughing, diarrhea, rhinorrhea and wheezing. Other solicited data included: prevention of pain and/or fever and treatment of pain and/or fever. Any = occurrence of the symptom regardless of intensity grade.
Time frame: From Day 1 (6 hours) to Day 7 after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 6 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 8 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 4 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 8 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 7 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 7 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 5 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 8 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 5 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 8 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 7 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 9 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 5 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 5 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 7 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 10 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 4 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 5 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 4 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 6 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 9 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 6 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 4 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 4 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 7 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 7 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 6 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 10 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 4 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 11 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 5 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 6 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 3 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 8 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 9 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 3 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 9 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 8 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 3 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 7 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 5 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 5 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 5 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 4 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 9 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 7 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 5 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 10 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 5 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 5 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 3 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 5 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 7 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 10 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 4 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 10 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 4 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 4 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 6 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 10 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 6 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 3 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 9 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 8 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 6 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 5 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 4 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 5 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 5 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 4 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 4 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 5 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 7 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 5 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 6 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 9 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 9 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 7 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 5 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 10 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 6 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 6 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 10 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 6 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 9 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 8 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 6 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 6 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 6 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 5 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
Primary
Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity
Assessed solicited systemic symptoms were: nausea, fatigue, myalgia, arthralgia, headache, fever (body temperature ≥ 38.0°C), chills, coughing, diarrhea, rhinorrhea and wheezing. Other solicited data included: prevention of pain and/or fever and treatment of pain and/or fever. Any = occurrence of the symptom regardless of intensity grade.
Time frame: Within 30 minutes after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 0 Participants |
Primary
Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity
Assessed solicited systemic symptoms were: nausea, fatigue, myalgia, arthralgia, headache, fever (body temperature ≥ 38.0°C), chills, coughing, diarrhea, rhinorrhea and wheezing. Other solicited data included: prevention of pain and/or fever and treatment of pain and/or fever. Any = occurrence of the symptom regardless of intensity grade.
Time frame: From Day 1 (6 hours) through Day 3 after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 6 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 6 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 5 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 4 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 7 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 6 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 4 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 8 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 5 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 5 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 6 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 4 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 8 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 5 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 4 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 4 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 6 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 5 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 4 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 6 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 8 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 3 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 5 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 5 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 6 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 7 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 6 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 3 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 3 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 3 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 4 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 5 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 7 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 4 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 9 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 3 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 4 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 5 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 5 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 6 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 4 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 8 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 5 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 7 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 6 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 5 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 9 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 5 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 4 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 4 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 5 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 4 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
Primary
Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity
Assessed solicited systemic symptoms were: nausea, fatigue, myalgia, arthralgia, headache, fever (body temperature ≥ 38.0°C), chills, coughing, diarrhea, rhinorrhea and wheezing. Other solicited data included: prevention of pain and/or fever and treatment of pain and/or fever. Any = occurrence of the symptom regardless of intensity grade.
Time frame: From Day 4 through Day 7 after each vaccination
Population: The analysis was based on the Solicited Safety set, which included all subjects in the Exposed population who provided post-vaccination reactogenicity data after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 7 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 7 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 7 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 2 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 5 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 5 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 4 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 3 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 6 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 6 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 8 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 2 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 8 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 5 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 7 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 1 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 2 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| Placebo 1 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 3 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 5 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 5 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 4 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 2 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 3 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 5 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 4 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 5 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 6 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 4 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 2 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 4 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 7 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 2 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 3 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 7 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 5 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 7 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 3 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 3 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 2 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 4 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 2 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 3 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 4 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 3 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 7 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 7 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 5 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 4 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 9 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 5 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 3 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 5 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 2 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 5 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 4 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (2nd) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Chills (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Arthralgia (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (2nd) | 2 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Myalgia (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Coughing (1st) | 6 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (2nd) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fatigue (1st) | 4 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever prevention (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (2nd) | 4 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Diarrhea (1st) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (1st) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Nausea (2nd) | 3 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Rhinorrhea (1st) | 6 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (2nd) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Pain/Fever treatment (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (2nd) | 4 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Wheezing (1st) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Fever (2nd) | 1 Participants |
| Placebo 3 Group | Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity | Any Headache (1st) | 3 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s)
SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity, congenital anomaly or birth defect. Any SAE = occurrence of the SAE regardless of intensity grade. Possibly or probably related SAE = SAE assessed by the investigator as possibly or probably related to the study vaccination. Other significant AE(s) assessed include unsolicited medically attended AEs, unsolicited AEs leading to study withdrawal, new onset of chronic diseases (NOCDs) and adverse events of special interest (AESIs). Medically attended AE = an adverse event that leads to an unscheduled visit to a healthcare practitioner. NOCD = an adverse event that represents a new diagnosis of a chronic medical condition that was not present or suspected in a subject prior to study enrollment.
Time frame: From study start (Day 1) until study completion (Day 394)
Population: The analysis was based on the Unsolicited Safety Set, which included all subjects in the Exposed population with unsolicited AE data collected from study start (Day 1) until study completion (Day 394).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 10 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 1 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 1 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 11 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 1 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 12 Participants |
| Placebo 1 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| Placebo 1 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 17 Participants |
| Placebo 1 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 0 Participants |
| Placebo 1 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 1 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 17 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 9 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 1 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 16 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 4 Participants |
| Placebo 2 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| Placebo 2 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| Placebo 2 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 15 Participants |
| Placebo 2 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 1 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 15 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 2 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 1 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 15 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 12 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AESI(s) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any NOCD(s) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any SAE(s) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any AE(s) leading to study withdrawal | 0 Participants |
| Placebo 3 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Possibly/probably related SAE(s) | 0 Participants |
| Placebo 3 Group | Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s) | Any medically attended AE(s) | 11 Participants |
Primary
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: From Day 1 to Day 28 after each vaccination
Population: The analysis was based on the Unsolicited Safety Set, which included all subjects in the Exposed population with unsolicited AE data collected after each vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV F 45 No Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 17 Participants |
| RSV F 45 No Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 8 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 15 Participants |
| RSV F 45 Alum Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 12 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 14 Participants |
| RSV F 45 MF59 Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 16 Participants |
| Placebo 1 Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 17 Participants |
| Placebo 1 Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 13 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 13 Participants |
| RSV F 90 No Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 15 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 14 Participants |
| RSV F 90 Alum Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 7 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 6 Participants |
| RSV F 90 MF59 Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 16 Participants |
| Placebo 2 Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 14 Participants |
| Placebo 2 Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 13 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 13 Participants |
| RSV F 135 No Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 10 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 14 Participants |
| RSV F 135 Alum Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 9 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 13 Participants |
| RSV F 135 MF59 Adj Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 15 Participants |
| Placebo 3 Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (2nd vacc.) | 10 Participants |
| Placebo 3 Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) (1st vacc.) | 17 Participants |
Primary
Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers
Immunogenicity was measured in terms of percentage of subjects with a ≥ 4-fold increase in serum anti-RSV NAb titers, from Day 1 (baseline) to Day 57 (28 days after the second dose).
Time frame: At Day 57
Population: The analysis was based on PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and and for whom immunogenicity results collected from Day 1 (baseline) up to Day 57 were available at Day 1 and Day 57.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 45 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 54 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 36 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 25 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 29 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 41 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 17 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 45 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 46 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers | 0 Percentage of subjects |
Secondary
Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers
Immunogenicity was measured in terms of GMTs of the serum anti-RSV neutralizing antibody (NAb) titers at Day 1, Day 29 (28 days after the first dose) and Day 181 (six months after the first dose).
Time frame: At Day 1, Day 29 and Day 181
Population: The analysis was based on the PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 1, Day 29 and at Day 181.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 576 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 237 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 893 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 587 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 947 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 184 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 450 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 983 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 340 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 234 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 215 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 236 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 289 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 1110 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 684 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 627 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 280 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 981 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 1208 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 254 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 597 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 242 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 260 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 233 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 1123 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 338 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 687 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 788 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 332 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 1602 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 380 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 764 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 1551 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 181 | 248 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 1 | 292 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers | Anti-RSV NAb, Day 29 | 286 Titers |
Secondary
Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N
Immunogenicity was measured in terms of the geometric mean titers (GMTs) of the serum total binding antibody to each of the RSV proteins F, G and N at Day 1 (baseline), Day 29 (28 days after the first dose), Day 57 (28 days after the second dose) and Day 181 (six months after the first dose).
Time frame: At Day 1, Day 29, Day 57 and Day 181
Population: The analysis was based on the PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 1, Day 29, Day 57 and Day 181.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 592 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 580 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 4904 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 480 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 64 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 62 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 109 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 106 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 671 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 123 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 8064 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 61 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 9641 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 64 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 122 Titers |
| RSV F 45 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 524 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 434 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 96 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 838 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 6584 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 461 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 55 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 55 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 525 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 11131 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 57 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 105 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 53 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 94 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 391 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 9707 Titers |
| RSV F 45 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 97 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 11639 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 55 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 586 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 513 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 467 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 101 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 106 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 10182 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 112 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 5312 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 120 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 60 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 420 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 58 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 916 Titers |
| RSV F 45 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 59 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 98 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 675 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 714 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 44 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 444 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 418 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 42 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 40 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 421 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 457 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 690 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 102 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 757 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 109 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 99 Titers |
| Placebo 1 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 43 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 107 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 396 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 13017 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 11470 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 6908 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 53 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 50 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 397 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 49 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 697 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 49 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 439 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 95 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 93 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 99 Titers |
| RSV F 90 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 418 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 55 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 92 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 423 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 10694 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 47 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 97 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 10131 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 484 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 89 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 112 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 46 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 470 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 486 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 6271 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 730 Titers |
| RSV F 90 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 54 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 443 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 87 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 44 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 89 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 11588 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 47 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 401 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 48 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 425 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 123 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 93 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 751 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 46 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 5824 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 508 Titers |
| RSV F 90 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 12841 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 46 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 57 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 60 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 345 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 100 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 763 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 454 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 90 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 727 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 660 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 412 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 78 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 684 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 101 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 424 Titers |
| Placebo 2 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 51 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 106 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 880 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 13252 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 462 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 524 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 11302 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 104 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 102 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 514 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 6157 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 54 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 55 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 59 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 493 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 60 Titers |
| RSV F 135 No Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 107 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 51 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 87 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 8651 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 426 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 13514 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 45 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 454 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 13483 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 417 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 91 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 97 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 417 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 43 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 94 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 685 Titers |
| RSV F 135 Alum Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 47 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 7041 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 910 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 13541 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 12158 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 65 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 57 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 51 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 53 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 112 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 109 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 89 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 98 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 569 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 471 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 439 Titers |
| RSV F 135 MF59 Adj Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 458 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 87 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 87 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 439 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 418 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 91 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 80 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 49 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 52 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 55 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 49 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 833 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 791 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 851 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 1 | 750 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 456 Titers |
| Placebo 3 Group | Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 1 | 392 Titers |
Secondary
Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer
Immunogenicity was measured in terms of percentage of subjects with a ≥ 4-fold increase in serum anti-RSV NAb titers from Day 1 to Day 29 (28 days after the first dose) and from Day 1 to Day 181 (six months after the first dose).
Time frame: At Day 29 and at Day 181
Population: The analysis was based on the PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 1, Day 29 and Day 181.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 32 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 48 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 29 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 58 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 30 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 5 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 17 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 25 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 14 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 42 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 15 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 50 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 35 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 14 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 27 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 57 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 42 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 17 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 181 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer | Anti-RSV NAb, Day 29 | 0 Percentage of subjects |
Secondary
Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N
Immunogenicity was measured in terms of the percentage of subjects with a ≥ 4-fold increase in serum total binding antibody to each of the RSV Proteins F, G and N from Day 1 (baseline) to all time points (Day 29 \[28 days after the first dose\], Day 57 \[28 days after the second dose\], and Day 181 \[six months after the first dose\]).
Time frame: At Day 29, Day 57 and Day 181
Population: The analysis was based on the PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 1, Day 29, Day 57 and Day 181.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 73 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 86 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 83 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 79 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 92 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 92 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 96 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 95 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 68 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 92 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 73 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 92 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 75 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 86 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 86 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 87 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 87 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 73 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 83 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 57 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 57 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 29 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein F, Day 181 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 181 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein N, Day 29 | 0 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0 Percentage of subjects |
Secondary
Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1
Immunogenicity was measured in terms of the percentage of subjects at Day 29 (28 days after the first dose), Day 57 (28 days after the second dose) and Day 181 (six months after the first dose) with serum anti-RSV NAb titers greater than the 3rd quartile of serum anti-RSV NAb titers at Day 1 (baseline).
Time frame: At Day 29, Day 57 and Day 181
Population: The analysis was based on the PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 1, Day 29, Day 57 and Day 181.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 64 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 78 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 95 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 50 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 79 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 83 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 64 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 95 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 100 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 18 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 17 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 9 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 92 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 83 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 87 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 73 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 92 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 79 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 95 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 91 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 65 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 17 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 13 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 13 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 91 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 91 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 68 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 82 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 100 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 91 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 74 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 100 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 181 | 17 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 29 | 25 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1 | Anti-RSV NAb, Day 57 | 25 Percentage of subjects |
Secondary
Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1
Immunogenicity was measured in terms of the percentage of subjects at Day 29 (28 days after the first dose), Day 57 (28 days after the second dose) and Day 181 (six months after the first dose), with serum total binding antibody titers to each of the RSV proteins F, G, and N greater than the 3rd quartile of serum total binding antibody titers to RSV protein F at Day 1 (baseline).
Time frame: At Day 29, Day 57 and Day 181
Population: The analysis was based on the PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 1, Day 29, Day 57 and Day 181.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 91 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 95 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 45 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 39 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 32 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 36 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 30 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 32 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 45 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 96 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 27 Percentage of subjects |
| RSV F 45 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 30 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 38 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 38 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 38 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 21 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 17 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 17 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 25 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 33 Percentage of subjects |
| RSV F 45 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 25 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 22 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 23 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 50 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 32 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 30 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 27 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 23 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 95 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 23 Percentage of subjects |
| RSV F 45 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 35 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 22 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 26 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 23 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 17 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 22 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 30 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 9 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 18 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 22 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 39 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 5 Percentage of subjects |
| Placebo 1 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 18 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 21 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 22 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 21 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 25 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 30 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 8 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 13 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 25 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 90 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 21 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 25 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 27 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 17 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 36 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 17 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 23 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 17 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 25 Percentage of subjects |
| RSV F 90 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 21 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 14 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 14 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 30 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 23 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 27 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 30 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 20 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 23 Percentage of subjects |
| RSV F 90 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 27 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 22 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 13 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 9 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 22 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 22 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 21 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 22 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 38 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 25 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 29 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 17 Percentage of subjects |
| Placebo 2 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 22 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 26 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 30 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 23 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 39 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 35 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 22 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 27 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 35 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 135 No Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 18 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 23 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 17 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 17 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 18 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 14 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 18 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 13 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 14 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 9 Percentage of subjects |
| RSV F 135 Alum Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 26 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 30 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 30 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 25 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 29 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 21 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 42 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 21 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 100 Percentage of subjects |
| RSV F 135 MF59 Adj Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 29 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 181 | 21 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 57 | 17 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 57 | 38 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 181 | 21 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 181 | 21 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 29 | 29 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein F, Day 57 | 25 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 57 | 25 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Gb, Day 29 | 25 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein Ga, Day 29 | 38 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 181 | 17 Percentage of subjects |
| Placebo 3 Group | Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1 | RSV Protein N, Day 29 | 33 Percentage of subjects |
Secondary
Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N
Immunogenicity was measured in terms of the ratio of RSV F serum Nab titers to each of the RSV F serum total binding antibody titers to RSV proteins F, G and N at Days 1, 29, 57 and 181.
Time frame: At Day 1, Day 29, Day 57 and Day 181
Population: The analysis was based on the PPS, which included all subjects in the FAS Immunogenicity population who were not excluded due to reasons defined prior to unblinding or analysis and for whom immunogenicity data were available at Day 1, Day 29, Day 57 and Day 181.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.59 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.45 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.87 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 8.37 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.27 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 10 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.62 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.12 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 8.95 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.13 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.073 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.14 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.79 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.99 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.076 Adjusted Geometric Mean Ratio |
| RSV F 45 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.19 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.17 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.27 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.057 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.056 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.11 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.73 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 3.95 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.47 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 2.40 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.53 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 11 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.095 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 12 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 13 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.48 Adjusted Geometric Mean Ratio |
| RSV F 45 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.099 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.11 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.061 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.52 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 2.10 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.12 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 3.18 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.20 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 11 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 12 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.063 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.63 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.21 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 12 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.43 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.89 Adjusted Geometric Mean Ratio |
| RSV F 45 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.13 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 2.96 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 1.80 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.17 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 2.86 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.47 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 1.96 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 3.24 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.43 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 3.32 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 2.07 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.21 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.46 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 1.77 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.18 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.42 Adjusted Geometric Mean Ratio |
| Placebo 1 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.18 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.059 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.047 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.16 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.51 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 10 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 13 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.086 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 12 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.48 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.43 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.11 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.076 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.54 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.36 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.38 Adjusted Geometric Mean Ratio |
| RSV F 90 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.19 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.76 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.17 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.53 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 10 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 13 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 9.76 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.44 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.20 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.045 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.058 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.097 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.35 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.81 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.64 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.076 Adjusted Geometric Mean Ratio |
| RSV F 90 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.098 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 13 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.51 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.12 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.090 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.44 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.73 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.039 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 11 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.83 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.46 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.15 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.065 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.049 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 9.91 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.88 Adjusted Geometric Mean Ratio |
| RSV F 90 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.18 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.31 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.21 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.25 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 3.13 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.43 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.39 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 1.70 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 1.75 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 2.93 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 2.61 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.37 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 2.82 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 1.36 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.23 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.82 Adjusted Geometric Mean Ratio |
| Placebo 2 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.18 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.34 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.65 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 9.83 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 11 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 8.78 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.16 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.043 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.056 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.074 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.30 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.079 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.10 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.15 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.55 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.46 Adjusted Geometric Mean Ratio |
| RSV F 135 No Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.36 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.068 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.15 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.26 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.26 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 11 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.33 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.21 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.061 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 11 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.00 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.034 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 9.21 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.054 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.029 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.11 Adjusted Geometric Mean Ratio |
| RSV F 135 Alum Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.54 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.14 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.083 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.31 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.078 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.047 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 0.43 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.59 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.045 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.18 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 9.58 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 0.39 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 11 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.51 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 9.56 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.081 Adjusted Geometric Mean Ratio |
| RSV F 135 MF59 Adj Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 0.69 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 181 | 1.77 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 1 | 2.57 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 29 | 2.98 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 57 | 3.11 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein F, Day 181 | 3.36 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 1 | 0.17 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 29 | 0.19 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 57 | 0.20 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Ga, Day 181 | 0.20 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 1 | 0.27 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 29 | 0.32 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 57 | 0.34 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein Gb, Day 181 | 0.35 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 1 | 1.34 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 29 | 1.60 Adjusted Geometric Mean Ratio |
| Placebo 3 Group | Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N | RSV Protein N, Day 57 | 1.65 Adjusted Geometric Mean Ratio |